According to the Zhitong Finance App, Zaiding Pharmaceutical (09688) announced results for the second quarter of 2026, with total revenue of US$106.3 million. Net product revenue for the second quarter of 2026 was $105.8 million. Net product revenue increased 11% month-on-month, thanks to Zelle's steady performance and continued growth in sales of Agamod. In the second half of 2026, the company looks forward to further stabilizing product sales, laying the foundation for a return to significant growth in 2027.
As of June 30, 2026, the total amount of cash and cash equivalents, short-term investments and restricted cash was US$717.5 million, compared to US$761.3 million as of March 31, 2026.
In the first half of 2026, total revenue was US$206 million; net loss was US$102 million; loss per share was US$0.09.
Dr. Du Ying, founder, chairman and CEO of Zaiding Pharmaceuticals, said, “Zaiding Pharmaceuticals is entering an exciting new chapter. Over the past few years, we have gradually grown from bringing innovative drugs to Chinese patients to a global biopharmaceutical company developing our own differentiated medicines for global patients. Today, our innovation pipeline is rapidly maturing. In less than two years, we have advanced the potential best-in-class DLL3 antibody drug conjugate (ADC) zocilurtatug pelitecan (zoci) from a new drug clinical trial application (IND) to global phase 3 clinical research, and our growing in-house developed product portfolio, including ZL-1503, makes us believe that innovation will increasingly become the core driving force for Zaiding Pharmaceutical's next phase of growth. At the same time, we continue to strengthen our commercialization business. This quarter, we further focused on commercialization priorities, achieved month-on-month revenue growth, maintained commercialization profits, and laid the foundation for a return to significant growth in 2027. All of these achievements help Zaiding Pharmaceuticals create long-term value for patients and shareholders.”
Dr. Rafael G. Amado, president of Zaiding Pharmaceuticals and head of global R&D, said, “We are very excited about the progress of the company's growing global pipeline. We expect three registered studies to be carried out by the end of the year, and we expect to submit our first US listing license application next year. Zoci has shown differentiating characteristics — strong systemic and intracranial activity and good safety features — to support its development in multiple treatment scenarios for small cell lung cancer and extrapulmonary neuroendocrine cancer. In the field of immunity, ZL-1503 is expected to simultaneously address inflammation and itching through the dual inhibition of IL-13 and IL-31. Combined with the extended half-life characteristics brought about by YTE transformation, we believe its differentiated properties can be expected to address significant unmet medical needs in one of the largest markets in the field of immunity. We look forward to sharing important clinical updates from these two programs in the second half of this year.”